Order Toll Free: 1-888-848-1945. You save an additional 20% by ordering online.

Welcome! Log in:

Forgot password?
Do I need an account to order?
River Pharmacy - Your Neighborhood Drugstore Online

Frequently Asked Questions

Is rimonabant (Acomplia/Zimulti) a diet or an anti-smoking drug?

Short Answer

Rimonabant is a diet drug developed by Sanofi-Synthelabo Inc. and marketed as Acomplia in the UK since June 2006 and other countries shortly after. It is sometimes used to help reduce smoking, but that form of use has not been approved of in all countries of sale.

Long Answer

Rimonabant is a selective CB1 blocker that act on the endocannabinoid (EC) system of the human body. An over-stimulated EC system is thought to play a role in obesity and in tobacco addiction, therefore these CB1 blockers are supposed to reduce this over stimulation.

These medications are still not in wide use worldwide and are quite new in relation to other medications. Time will tell how CB1 blockers are tolerated by people now that it is becoming more widely available.

Few drugs are widely approved for long-treatment of obesity. These include the lipase inhibitor orlistat and the drug sibutramine. As with most medications, each of these products has been limited by their side effects.

Searches related to rimonabant:

  • zimulti
  • chantix
  • sibutramine
  • accomplia
  • orlistat
  • diabetes

Additional Information

Rimonabant (SR141716) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia. It is believed, although not confirmed, that if the drug is approved in the United States, it will be sold under the trade name Zimulti.
drugdevelopment-technology.com/ projects/rimonabant
The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption and the phenomena of dependence / habituation. Sanofi-Aventis worked on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.
heartdisease.about.com/od/ dietandobesity/a/rimonabant5.htm
Side effects included depression, anxiety and nausea. About 1 in 8 out of 3040 patients taking rimonabant dropped out of a study due to side effects.